Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 127(3):451–455. https://doi.org/10.1016/j.ygyno.2012.09.008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blair HA, Deeks ED (2015) Albumin-bound paclitaxel: a review in Non-small Cell Lung Cancer. Drugs 75(17):2017–2024. https://doi.org/10.1007/s40265-015-0484-9

Article  CAS  PubMed  Google Scholar 

Chen J, Shi D, Liu X, Fang S, Zhang J, Zhao Y (2012) Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis. BMC Cancer 12:464. https://doi.org/10.1186/1471-2407-12-464

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chopra S, Kalra B, Mulani J, Jain J, Gurram L, Mittal P, Alone M, Ghosh J, Rath S, Gulia S, Gupta S (2022) Salvage (re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer. Int J Radiat Oncol Biol Phys 114(4):812–819. https://doi.org/10.1016/j.ijrobp.2022.07.002

Article  PubMed  Google Scholar 

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324. https://doi.org/10.1158/1078-0432.Ccr-05-1634

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. https://doi.org/10.1200/jco.2005.04.937

Article  CAS  PubMed  Google Scholar 

Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, Wang P, Cai W, Zhou Y (2019) Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol 139:16–23. https://doi.org/10.1016/j.critrevonc.2019.04.021

Article  PubMed  Google Scholar 

Han S, Liu X, Ju S, Mu W, Abulikemu G, Zhen Q, Yang J, Zhang J, Li Y, Liu H, Chen Q, Cui B, Wu S, Zhang Y (2023) New mechanisms and biomarkers of lymph node metastasis in cervical cancer: reflections from plasma proteomics. Clin Proteom 20(1):35. https://doi.org/10.1186/s12014-023-09427-8

Article  CAS  Google Scholar 

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044

CAS  PubMed  Google Scholar 

Jiang P, Deng X, Qu A, Jiang W, Guo F, Han Q, Guo H, Wang J (2023) Image Guidance volume-modulated Arc Radiation Therapy concurrently with nab-paclitaxel plus cisplatin for patients with locally Advanced Cervical Cancer: a single-arm dose escalation Trial. Int J Radiat Oncol Biol Phys 115(5):1197–1204. https://doi.org/10.1016/j.ijrobp.2022.11.011

Article  PubMed  Google Scholar 

Kim HJ, Chang JS, Koom WS, Lee KC, Kim GE, Kim YB (2018) Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. Gynecol Oncol 151(2):208–214. https://doi.org/10.1016/j.ygyno.2018.08.029

Article  PubMed  Google Scholar 

Leath CA 3rd, Straughn JM Jr. (2013) Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129(1):251–257. https://doi.org/10.1016/j.ygyno.2012.12.035

Article  CAS  PubMed  Google Scholar 

Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ (2020) Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis. Sci Rep 10(1):530. https://doi.org/10.1038/s41598-019-57380-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zeng J, Huang M, An J, Bai P, Wu L, Zhang R (2017) A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. Cancer 123(3):420–425. https://doi.org/10.1002/cncr.30328

Article  CAS  PubMed  Google Scholar 

Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, Peng W, Fang Z, Xia B, Chen X, Song K, Wang Y, Zou D, Wang YC, Han Y, Feng X, Yuan J, Guo S, Meng X, Feng C, Chen Y, Yang J, Fan J, Wang J, Ai J, Ma D, Sun C (2024) Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol 25(1):76–85. https://doi.org/10.1016/s1470-2045(23)00531-4

Article  CAS  PubMed  Google Scholar 

Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649–4655. https://doi.org/10.1200/jco.2009.21.8909

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14(6):1858–1867. https://doi.org/10.1200/jco.1996.14.6.1858

Article  CAS  PubMed  Google Scholar 

Pascual-Pasto G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, Vila-Ubach M, Muñoz-Aznar O, Suñol M, Burgueño V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J, Carcaboso AM (2022) SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. J Control Release 342:81–92. https://doi.org/10.1016/j.jconrel.2021.12.035

Article  CAS  PubMed  Google Scholar 

Shi D, Jiang K, Fu Y, Fang R, Liu XI, Chen J (2016) Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition. Oncol Lett 11(5):3251–3258. https://doi.org/10.3892/ol.2016.4399

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 11(2):e197–e206. https://doi.org/10.1016/s2214-109x(22)00501-0

Article  CAS  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Tai IT, Tang MJ (2008) SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11(6):231–246. https://doi.org/10.1016/j.drup.2008.08.005

Article  CAS  PubMed  Google Scholar 

Takekuma M, Hirashima Y, Ito K, Tsubamoto H, Tabata T, Arakawa A, Itani Y, Furukawa N, Murakoshi H, Takeuchi S (2012) Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol 126(3):341–345. https://doi.org/10.1016/j.ygyno.2012.05.010

Article  CAS  PubMed  Google Scholar 

Vergote I, Ray-Coquard I, Lorusso D, Oaknin A, Cibula D, Van Gorp T (2023) Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline? Expert Opin Investig Drugs 32(3):201–211. https://doi.org/10.1080/13543784.2023.2179483

Article  CAS  PubMed  Google Scholar 

Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, Teng YE, Cai L, Yan M, Wang X, Jiang Z, Pan Y, Luo J, Shao Z, Wu J, Guo X, Hu X (2022) A randomized phase 3 trial of Gemcitabine or Nab-Paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun 13(1):4025. https://doi.org/10.1038/s41467-022-31704-7

Article  CAS  PubMed  PubMed Central